SCHEMBL296028

SCHEMBL296028

CCCC[n+]1cccc(C)c1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.57
KDM4E B2RXH2 1/20 0.52
APAF1 O14727 1/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
RAD52 P43351 1/20 0.52
BLM P54132 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
ABCB11 O95342 1/20 0.50
ESR1 P03372 1/20 0.50
PGR P06401 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM1 P11229 1/20 0.50
DRD1 P21728 1/20 0.50
TBXA2R P21731 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29394041 1.00 HTT (0.57) HTTKDM4EAPAF1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL29465194 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Iodide SCHEMBL16107451 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Bromide SCHEMBL29987617 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Water SCHEMBL15375382 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Bromide SCHEMBL17926315 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL17926382 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Bromide SCHEMBL194547 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Fluoride Ion SCHEMBL30213090 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA
Hydrochloric Acid SCHEMBL322540 0.98 HTT (0.55) HTTKDM4EAPAF1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122085568-A Ion gel electrolyte composition capable of being subjected to room-temperature in-situ spontaneous polymerization, electrolyte and application 2026-05-26 CN claimed
US-20250196021-A1 METHODS OF SOLVENT DISPLACEMENT FOR METAL-CONTAINING IONIC LIQUIDS CHEVRON PHILLIPS CHEMICAL COMPANY LP 2025-06-19 US claimed
US-20250036046-A1 TRANSFER BELT AND IMAGE FORMING APPARATUS INCORPORATING TRANSFER BELT RICOH COMPANY, LTD. (JP) 2025-01-30 US claimed
EP-4498167-A1 TRANSFER BELT AND IMAGE FORMING APPARATUS INCORPORATING TRANSFER BELT Ricoh Company, Ltd. (JP) 2025-01-29 EP claimed
EP-4470972-A1 PROCESS FOR PRODUCING ONIUM SALTS OF BIS(FLUOROSULFONYL)IMIDE SPECIALTY OPERATIONS FRANCE (FR) 2024-12-04 EP claimed
CN-117285721-A Carboxylated porous aromatic skeleton material and preparation method and application thereof 合肥学院 2023-12-26 CN claimed
EP-3204977-B1 ELECTROLYTE FOR RECHARGEABLE ELECTROCHEMICAL CELL EOS ENERGY TECH HOLDINGS LLC (US) 2023-12-20 EP claimed
EP-3835386-B1 TWO COMPONENT (2K) CURABLE ADHESIVE COMPOSITION HENKEL AG & CO KGAA (DE) 2023-11-15 EP claimed
CN-114787298-B Two-component (2K) curable adhesive composition 汉高股份有限及两合公司 2023-10-31 CN claimed
CN-116322077-A Hole transport layer solution with photoactive layer passivation effect and preparation and application thereof 上海钙蓝时代光电科技有限公司 2023-06-23 CN claimed
EP-1641882-A1 IONIC CONDUCTING GELS, PREPARATION METHOD THEREOF AND USE OF SAME Centre National de la Recherche Scientifique (FR) 2006-04-05 EP claimed
WO-2006031814-A2 ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE COMBIMATRIX CORPORATION (US) 2006-03-23 WO claimed
WO-2006029788-A1 METHOD FOR SEPARATING HYDROGEN CHLORIDE AND PHOSGENE BASF AKTIENGESELLSCHAFT (DE) 2006-03-23 WO claimed
US-20050232981-A1 Compositions capable of facilitating penetration across a biological barrier CHIASMA, INC. 2005-10-20 US claimed
WO-2005094785-A2 COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER CHIASMA, LTD. (IL) 2005-10-13 WO claimed
US-20050136103-A1 Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation CHIASMA, INC. 2005-06-23 US claimed
US-20050058702-A1 Compositions capable of facilitating penetration across a biological barrier CHIASMA, INC. 2005-03-17 US claimed
WO-2005007746-A1 IONIC CONDUCTING GELS, PREPARATION METHOD THEREOF AND USE OF SAME CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2005-01-27 WO claimed
US-20040146549-A1 Amino acid sequences capable of facilitating penetration across a biological barrier CHIASMA, INC. 2004-07-29 US claimed
EP-1362572-A1 Cosmetic composition comprising at least one particular organic salt and its use for cleansing and/or conditioning keratinous materials, use of a particular organic salt as conditioning agent for said materials and process for cosmetic treatment L'OREAL (FR) 2003-11-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050136103-A1 Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation CFTR, SLC47A1, SLC47A2 HTT 677/4885KDM4E 4611/4885APAF1 1149/4885
US-20050232981-A1 Compositions capable of facilitating penetration across a biological barrier MMP8, PGF, AQP1 HTT 684/4885KDM4E 4876/4885APAF1 481/4885
US-20040146549-A1 Amino acid sequences capable of facilitating penetration across a biological barrier SLC7A1, SLC1A5, SLC3A2 HTT 366/4885KDM4E 4787/4885APAF1 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.